Navigation Links
Cytochroma Closes $45 Million Series C Financing
Date:7/30/2008

Proceeds to Advance Clinical Development Of Lead Drug Candidates

MARKHAM, ON, July 30 /PRNewswire/ - Cytochroma today announced the closing of a CDN $45 million Series C financing. The financing was led by a new investor, Mitsubishi Tanabe Pharma Corporation ("MTPC"), and supported by a number of existing investors including Vengrowth Advanced Life Sciences Fund Inc., Caisse de Depot et Placement du Quebec, Novo A/S, Canadian Medical Discoveries Fund Inc., T(2)C(2)/Bio 2000 Limited Partnership, GrowthWorks Canadian Fund Ltd., BDC Capital Inc., and VentureLink Brighter Future Fund Inc.

Charles W. Bishop, PhD, Cytochroma's President and CEO stated, "We are grateful for the strong support of MTPC and our existing investors as we work to achieve our goal of becoming an integrated specialty pharmaceutical company. This latest funding provides Cytochroma with the financial capability to aggressively drive the development of our clinical-stage therapeutic pipeline."

The new funding will be used to advance Cytochroma's portfolio of vitamin D-based therapeutics into mid- and late-stage clinical trials. Cytochroma's product candidates target disorders related to altered vitamin D metabolism in chronic kidney disease ("CKD") patients, and include CTA018 and CTAP201 for the treatment of secondary hyperparathyroidism ("SHPT"), and CTAP101 for the treatment of vitamin D insufficiency. These three lead products address significant markets that are expected to grow to more than $1.4 billion annually by 2013 in North America.

In connection with the financing, Seiichi Kiso, PhD, MBA, General Manager, Business Development & Licensing Department of MTPC, and Joseph Regan, GrowthWork's Vice President, Investments, have joined Cytochroma's Board of Directors bringing the number of directors to six. Elizabeth Douville, PhD, Vice President of GeneChem Management Inc., has retired from the Board after more than nine years of service with the Company.

<
'/>"/>
SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cytochroma Appoints R. Richard Wieland II As CFO
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
4. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
5. AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury
6. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
7. MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
8. Raptor Pharmaceuticals Closes $10 Million Private Placement
9. China Pharma Holdings, Inc. Closes $10 Million Financing
10. Transdel Pharmaceuticals Closes $4 Million Financing
11. Dilon Technologies Closes First Quarter With Record Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
(Date:5/16/2013)... 16, 2013 ISPE ... Myers, CAE, to the newly created position of ... role, Myers will be responsible for stimulating ISPE’s ... strategies, advancing the Society’s Member-led and staff-driven business ... to refine organizational, membership and product marketing. , ...
(Date:5/16/2013)... Kitware , a leading provider of ... II SBIR funding from the U.S. Department of ... high performance computing (HPC) simulation and computation framework. ... select only the toolkits and applications needed to ... tasks. , Manufacturers increasingly rely on simulation ...
(Date:5/16/2013)... 16, 2013 On average, developing a ... one billion dollars. Despite this investment, less than 10% ... high, is your clinical trial design optimally structured to ... outcomes? , Dr. Frederic Sax, Global Head of the ... use of data, information and technology in upfront clinical ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... announced that Scott Jackson, chief executive officer, is scheduled to ... in New York and the 2008 Mid-Atlantic Capital Conference in ... an update on the company,s clinical development programs. The ... , Piper Jaffray Health ...
... 25 /PRNewswire/ - EastMed Inc., the medical manufacturing company ... received FDA clearance to market its flagship product, uresta(TM) ... are delighted to get the official word from the ... Inc. "Uresta (TM) Continence Care offers an innovative and ...
... /PRNewswire/ - The Atlantica BioEnergy Task Force today completed ... business and education leaders from across Atlantic Canada and ... sector. , "The global forest industry is ... to look for environmentally sustainable ways to best use ...
Cached Biology Technology:Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference 2Atlantica Bioenergy Task Force hosts industry and government leaders 2Atlantica Bioenergy Task Force hosts industry and government leaders 3
(Date:5/16/2013)... Integrated Biometrics patented LES (Light Emitting ... film transistor camera introduces Sherlock, a fingerprint scanner ... the smallest and lightest form factor available on ... ID FAP 45, Certified scanner is highly efficient ... weight when compared to optical scanners. ...
(Date:5/16/2013)... use of genome-wide analysis (GWA), where the entirety of ... genomic mutations or variants which can cause health problems ... However, it can also pose major ethical problems if ... of Human Genetics (ESHG) published on line today (16 ... Genetics ., Many services based on whole genome and ...
(Date:5/16/2013)... 2013 Reportlinker.com announces that a ... its catalogue: Global Biometric ... http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems Lack ... such as photographs, passwords and PIN codes ... in last few years. Security threats such ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7
... in French and Spanish . ... endorsed science projects assembled from researchers in more than 60 ... period to March 2009 to allow for observations during the ... WMO and ICSU, IPY spearheaded efforts to better monitor and ...
... 25, 2009 The first international society dedicated to ... orthopaedic conditions has been formed. The Biologic Orthopaedic ... Tuesday, February 24, 2009 at the Venetian Hotel, Las ... the American Academy of Orthopaedic Surgeons. BOS Presiding ...
... from Queen Mary, University of London have discovered ... primitive bacteria, may also explain how plants and ... signal transduction systems (TCSTs) have long been recognised ... their responses to changes in their environment. But ...
Cached Biology News:Polar research reveals new evidence of global environmental change 2Polar research reveals new evidence of global environmental change 3New orthopaedic society launched to promote research, use of biologic treatments 2
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
GBL Antibody...
...
Biology Products: